Evidence map›Paper›PMID 39773803›Full record

ArticleBMJ open2025

Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseases.

Melek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, Filippo Fagni, Selahattin Alp Temiz, Christine Meder, Peter Dietrich, Till Orlemann, Johanna Mößner, Verena Schoenau and 20 more

Abstract readMulticenter Study
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Melek Yalcin MutluUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0003-0598-5737
Arnd KleyerUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0002-2026-7728
Gerhard KroenkeUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Filippo FagniUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0002-6122-0774
Selahattin Alp TemizUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0003-0804-3198
Christine MederUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Peter DietrichUniversitätsklinikum Erlangen Department of Medicine 1, Kussmaul Research Campus & Ludwig Demling Endoscopy Center of Excellence, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Till OrlemannUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Johanna MößnerUniversitätsklinikum Erlangen Department of Medicine-2, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Verena SchoenauUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0003-0586-9824
Daniela BohrUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Louis SchusterUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Fabian HartmannUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Ioanna MinopoulouUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Moritz LeppkesUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Andreas RammingUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Milena L PachowskyUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Florian SchuchRheumatology Practice Erlangen, Erlangen, Germany.
Monika RonnebergerRheumatology Practice Erlangen, Erlangen, Germany.
Stefan KleinertRheumatology Practice Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-2588-7547
Axel J HueberUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0001-6454-1234
Karin MangerUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Bernhard MangerUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0003-2375-0069
Raja AtreyaUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Carola BerkingUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Michael SticherlingUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Markus F NeurathUniversitätsklinikum Erlangen, Deutsches Zentrum fuer Immunotherapie, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Georg SchettUniversitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0001-8740-9615
David Simon *Universitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany.ORCID http://orcid.org/0000-0001-8310-7820
Koray Tascilar *Universitätsklinikum Erlangen Department of Medicine-3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bayern, Germany koray.tascilar@uk-erlangen.de.ORCID http://orcid.org/0000-0002-8109-826X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAlthough patients with immune-mediated inflammatory diseases (IMID) are thought to be more susceptible to viral infections, it is unclear whether their presentation differs between patients with IMID and healthy controls. This study aimed to investigate the symptom pattern of common viral infections in patients with IMID and compare it with controls without IMIDs.

designA cross-sectional study conducted between 1 February and 30 April 2020, using a questionnaire.

settingSeven tertiary regional care centers in Germany, which specialised in the care of patients with IMID (namely, in gastroenterology, dermatology, rheumatology and immunology clinical care).

participantsOne thousand nine hundred nine participants completed the survey (757 patients with IMID; 1152 non-IMID controls). PRIMARY OUTCOME MEASURE: The occurrence of 11 common viral illness symptoms within the preceding 3 months in patients with IMID and non-IMID controls.

resultsSymptom data were clustered, based on number and co-occurrance, into 3 major clusters and 2 subclusters ranked by the average number of symptoms. Patients with inflammatory bowel disease and psoriasis were significantly overrepresented in the lower-frequency subcluster of the polysymptomatic cluster. Patients with rheumatoid arthritis were overrepresented in the lower-frequency subclusters of the intermediate and oligo-/asymptomatic clusters. Controls were over-represented only in the higher-frequency subclusters of each major cluster where none of the IMIDs were over-represented. Spondyloarthritis and other IMIDs were also overrepresented in the low-frequency subcluster, but the results were not significant. Overall, patients with rheumatoid arthritis patients reported fewer symptoms (rate ratio=0.68, 95% CI, 0.59 to 0.80) than non-IMID controls.

conclusionPatients with IMID are over-represented in low-frequency subclusters, even among individuals who have reported a broad range of viral infection symptoms. This pattern suggests that the manifestations of viral infections are different between patients with IMID and controls, thus challenging the accurate and early diagnosis of infections.

Indexed as

Virus DiseasesAdultAgedArthritis, RheumatoidCase-Control StudiesCross-Sectional StudiesFemaleGermanyHumansInflammatory Bowel DiseasesMaleMiddle AgedPsoriasisSurveys and QuestionnairesRespiratory infectionsRheumatology

Identifiers

PMID39773803
PMCPMC11749532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.